Currently, it costs a public bank approximately USD $2,000 to collect, test, and process a unit of cord blood for storage. In order to accept donations at no cost, public banks require income to support themselves. This income can come from federal funding, the profit margin of private banking, or from selling donated cord blood units for research. Alternatively, it can come from a combination of the above.
Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform
New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration
WARREN, New Jersey, Aug. 21, 2017 /PRNewswire/ — Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.
Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:
- Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets
- Proprietary allogeneic (“readily accessible”) immunotherapy platform
- 200+ issued and pending patents in cell therapy; robust IP for placental stem cells
- Broad fully human antibody-CAR constructs
- IND-ready joint CD38 immuno-oncology programs
- Commercial-stage functional regeneration products Biovance® and Interfyl®* and pipeline assets
- LifeBankUSA stem cell biorepository with two decades operating expertise
Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity’s ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.
[Read more…]
Luxcel, Axiogenesis, and BMG LABTECH Secure €2.5M for Cell Metabolism Analysis Platform
Luxcel Biosciences, Axiogenesis, and BMG LABTECH have announced €2.5M in funding to develop and launch a cell metabolism analysis platform, MetaCell™.
Together, these companies European technology subject matter experts (SMEs) have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot. The funding will support development of a cell metabolism analysis platform that aims to become integral to in vitro cell biology and drug development. [Read more…]
Axiogenesis Secures Funding for Market Expansion from Sino-German High-Tech Fund
Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
What Types of Mesenchymal Stem Cell (MSC) Research Are Getting Funded?
To analyze trends within the mesenchymal stem cell (MSC) industry, it is valuable to consider grant rate data. Previously, the U.S. federal government operated an online tool called CRISP (“Computer Retrieval of Information on Scientific Projects”). It was a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other U.S. research institutions. The database allowed users to search the CRISP interface for grants funding for specific types of scientific research, using text-based search terms.
However, that has since been replaced by RePORTer (Research Portfolio Online Reporting Tools)1, a more powerful database and search tool supported by the U.S. Department of Health and Human Services. RePORTer allows users to search a comprehensive repository of National Institutes of Health (NIH) funded research projects resulting from NIH funding. [Read more…]